Inhibition of hepatitis viral replication by siRNA

Jian Wu, Kiran Mayi Nandamuri

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Small interfering RNA (siRNA)-mediated sequence-specific gene silencing is a powerful tool to inhibit endogenous and exogenous gene expression, and it holds great potential to prevent and eradicate viral infection, for which existing therapy is inadequate, such as HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV). A number of studies have documented the effectiveness of siRNA against HBV or HCV at various regions of the viral genome in infected human hepatoma cell lines. Selected siRNA may reduce the production of viral replicons, as well as structural or non-structural proteins by > 90%. Only a few in vivo studies that demonstrated the efficacy of siRNA in the suppression of HBV replication in mice are available. Thus, reliable models of HBV and HCV infection in small animals or non-human primates are needed to evaluate the delivery and efficacy of siRNA as a therapeutic modality for viral hepatitis.

Original languageEnglish (US)
Pages (from-to)1649-1659
Number of pages11
JournalExpert Opinion on Biological Therapy
Volume4
Issue number10
DOIs
StatePublished - Oct 2004

Fingerprint

Viruses
Small Interfering RNA
Hepatitis
Hepatitis B virus
Hepacivirus
Virus Diseases
Replicon
Viral Genome
Genes
Gene Silencing
Virus Replication
Primates
Hepatocellular Carcinoma
HIV
Gene expression
Gene Expression
Cell Line
Animals
Cells
Therapeutics

Keywords

  • Antisense
  • Hepatitis B virus
  • Hepatitis C virus
  • Ribozyme
  • Small interfering RNA

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

Inhibition of hepatitis viral replication by siRNA. / Wu, Jian; Nandamuri, Kiran Mayi.

In: Expert Opinion on Biological Therapy, Vol. 4, No. 10, 10.2004, p. 1649-1659.

Research output: Contribution to journalArticle

Wu, Jian ; Nandamuri, Kiran Mayi. / Inhibition of hepatitis viral replication by siRNA. In: Expert Opinion on Biological Therapy. 2004 ; Vol. 4, No. 10. pp. 1649-1659.
@article{0b0a242715fe40c0ae5987e5f67b1660,
title = "Inhibition of hepatitis viral replication by siRNA",
abstract = "Small interfering RNA (siRNA)-mediated sequence-specific gene silencing is a powerful tool to inhibit endogenous and exogenous gene expression, and it holds great potential to prevent and eradicate viral infection, for which existing therapy is inadequate, such as HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV). A number of studies have documented the effectiveness of siRNA against HBV or HCV at various regions of the viral genome in infected human hepatoma cell lines. Selected siRNA may reduce the production of viral replicons, as well as structural or non-structural proteins by > 90{\%}. Only a few in vivo studies that demonstrated the efficacy of siRNA in the suppression of HBV replication in mice are available. Thus, reliable models of HBV and HCV infection in small animals or non-human primates are needed to evaluate the delivery and efficacy of siRNA as a therapeutic modality for viral hepatitis.",
keywords = "Antisense, Hepatitis B virus, Hepatitis C virus, Ribozyme, Small interfering RNA",
author = "Jian Wu and Nandamuri, {Kiran Mayi}",
year = "2004",
month = "10",
doi = "10.1517/14712598.4.10.1649",
language = "English (US)",
volume = "4",
pages = "1649--1659",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Inhibition of hepatitis viral replication by siRNA

AU - Wu, Jian

AU - Nandamuri, Kiran Mayi

PY - 2004/10

Y1 - 2004/10

N2 - Small interfering RNA (siRNA)-mediated sequence-specific gene silencing is a powerful tool to inhibit endogenous and exogenous gene expression, and it holds great potential to prevent and eradicate viral infection, for which existing therapy is inadequate, such as HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV). A number of studies have documented the effectiveness of siRNA against HBV or HCV at various regions of the viral genome in infected human hepatoma cell lines. Selected siRNA may reduce the production of viral replicons, as well as structural or non-structural proteins by > 90%. Only a few in vivo studies that demonstrated the efficacy of siRNA in the suppression of HBV replication in mice are available. Thus, reliable models of HBV and HCV infection in small animals or non-human primates are needed to evaluate the delivery and efficacy of siRNA as a therapeutic modality for viral hepatitis.

AB - Small interfering RNA (siRNA)-mediated sequence-specific gene silencing is a powerful tool to inhibit endogenous and exogenous gene expression, and it holds great potential to prevent and eradicate viral infection, for which existing therapy is inadequate, such as HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV). A number of studies have documented the effectiveness of siRNA against HBV or HCV at various regions of the viral genome in infected human hepatoma cell lines. Selected siRNA may reduce the production of viral replicons, as well as structural or non-structural proteins by > 90%. Only a few in vivo studies that demonstrated the efficacy of siRNA in the suppression of HBV replication in mice are available. Thus, reliable models of HBV and HCV infection in small animals or non-human primates are needed to evaluate the delivery and efficacy of siRNA as a therapeutic modality for viral hepatitis.

KW - Antisense

KW - Hepatitis B virus

KW - Hepatitis C virus

KW - Ribozyme

KW - Small interfering RNA

UR - http://www.scopus.com/inward/record.url?scp=5644250628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5644250628&partnerID=8YFLogxK

U2 - 10.1517/14712598.4.10.1649

DO - 10.1517/14712598.4.10.1649

M3 - Article

C2 - 15461576

AN - SCOPUS:5644250628

VL - 4

SP - 1649

EP - 1659

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 10

ER -